In the study of De Giorgi et al., triple-negative, HER2+, and HER2–ER+ subtypes of breast cancer were also independently analyzed, in addition to the overall results [16]; while all the other studies [12, 13, 21, 22] on breast cancer only focused on specific breast cancer subtypes. This evidence concerns the gene ERBB2 and breast carcinoma.